Last reviewed · How we verify
NCT04812236
Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness
Phase 4 trial testing Wulingsan single decoction granules in Metabolic Syndrome in 320 participants. Status unknown.
28 February 2023
Quick facts
| Lead sponsor | Jiangsu Famous Medical Technology Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 320 |
| Start date | 1 April 2021 |
| Primary completion | 28 February 2023 |
| Estimated completion | 1 May 2023 |
Drugs / interventions tested
- Wulingsan single decoction granules — full drug profile →
- Wulingsan co-decoction granules — full drug profile →
- Wuling Powder
- Wulingsan granule simulant — full drug profile →
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
Jiangsu Famous Medical Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, a randomized, partially double-blind, controlled, multi-center clinical research method was used. A total of 4 groups were designed, namely, single decoction group, co-decoction group, powder group and simulation group. The four groups of patients all received basic health education, diet control and increased exercise guidance. All the patients in the group have taken western medicine according to their own conditions and followed the doctor's instructions for hypoglycemic, blood pressure, and lipid-lowering treatments. After joining the group, they continue to take the medicine at the original dose, and the patients are advised not to change the medicine during the observation period. Take 12 weeks as a course of treatment, and set the observation period to 12 weeks. Follow up every 4 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04812236
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Jiangsu Famous Medical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07129499 — Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas · NA · not yet recruiting
- NCT07123116 — Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas · NA · not yet recruiting
- NCT06613373 — An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Bre · Phase 4 · not yet recruiting
- NCT06537674 — Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive · not yet recruiting
- NCT06136026 — Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04812236 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Famous Medical Technology Co., Ltd.
- Last refreshed: 23 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04812236.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing